News Release

Beijing Clinical Investigation meeting for Clinical Studies in China

Date: Jun 10, 2002

TSX Venture Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

Nanning Maple Leaf Pharmaceutical Co., Ltd., (NMLP) a subsidiary of International Wex Technologies Inc. (the "Company') held a meeting in Beijing on May 23, 2002 to conclude the clinical development plan for Chinese studies. Experts from the various specialties of pharmacology, toxicology, Pharmacokinetics and clinicians in Oncology and Neurology participated along with three investigators (doctors who will lead the clinical trials).

Dr. Susan Lu, the Company's clinical co-ordinator stated, "The meeting was very successful as all parties agreed to following one format, keeping in mind the safety consideration for participants. The resulting phase I design is a randomized, double blind, ascending dose study involving up to 56 subjects. This design will now be presented for approval to the ethic committees of the selected hospitals. The study will start soon. According to the SDA's guidelines, the phase II and III clinical studies will need to enroll approximately 100 and 300 patients respectively. We believe that we will be able to complete the studies in China earlier than in Canada due to a larger pool of patients available."

The Company will focus on pain management in China in the phase II and III studies.

In the area of neuro-bioscience, the Company is focusing on the fields of pain management, drug addiction treatment and anaesthesia. The Company is developing products that contain a sodium channel blocking compound and derivatives extracted from natural organic substance using its proprietary manufacturing technology.

For additional information on our products, view the Company website at http://www.wextech.ca or call Howard Milne, V.P. Corporate Communications, at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Canadian Venture Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.